Leiden Early Drug Discovery & Development

LED3 Lectures

The LED3 hub, consisting of researchers from the Leiden Institute of Chemistry (LIC), the Institute of Biology Leiden (IBL) and the Leiden Academic Centre for Drug Research (LACDR), is very excited to organize the “LED3 Lectures”. This lecture series brings world-leading researchers in the field of early drug discovery to our university and exposes our students to the many different aspects of top science conducted in this area.

Furthermore, it strengthens the network and the active exchange of researchers across our three member institutes and, in this way, fosters interdisciplinary research at Leiden University and beyond.

The LED3 Lectures are held approximately once a month. The format is a 45 min lecture followed by a Q&A session and an informal "meet-and-greet" outside the lecture hall, in which interested participants can get in direct contact with the speakers.

Previous speakers

Sarah O'Connor (MPI, Jena, GER)
Cheryl Arrowsmith (Toronto, CAN)
Hans Clevers (Roche, Basel, CH)
Dirk Trauner (UPenn, USA)
Jeremy Baskin (Cornell, USA)
Chris Schofield (Oxford, UK)
Maike Hansen (Nijmegen, NL)
Gonçalo Bernardes (Cambridge, UK)
Dan Nomura (UC Berkeley)
Ken Jacobson (NIH, Bethesda, Maryland)
Kathrin Lang (ETH Zürich)
Clemens Mayer (University of Groningen)
Christian Ottmann (TU Eindhoven)
Mohammad R. Seyedsayamdost (Princeton University)
Dario Neri (ETH, Switzerland)
Christian Heinis (EPFL)
Tom Grossmann (VU Amsterdam)
Akane Kawamura (Newcastle University/University of Oxford)
Carolyn Bertozzi (Stanford University)
Craig Crews (Yale University)
Matt Bogyo (Stanford University)
Andreas Marx (Universität Konstanz)
Benjamin Cravatt (The Scripps Research Institute)
Tom Wennekes (Universiteit Utrecht)
Benjamin G. Davis (University of Oxford)
Chris Schofield (Oxford University, Chemistry Research Laboratory)
Roderich Süssmuth (Technische Universität Berlin)
John Sutherland (University of Cambridge)
Joseph Fox (University of Delaware)
Peter Cresswell (Yale University)
Derek Lowe (Novartis Institutes for BioMedical Research)